CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
bevacizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01898130
NCT01898130Phase 2Completed
CompareCT.gov

A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

Northwestern University·interventional·Posted Jul 12, 2013·Updated Sep 17, 2019

In Brief

A Phase 2 clinical trial evaluating bevacizumab and quality-of-life assessment for Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 27 participants across 4 sites.

Detailed Summary

This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the growth of new blood vessels; therefore it might stop tumor growth and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 12, 2013
Enrollment StartNov 27, 2013
Primary CompletionMar 23, 2017
Study CompletionSep 5, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.0 years ago

Interventions

bevacizumabbiological

Given IV

quality-of-life assessmentprocedure

Ancillary studies